NTLA (Intellia Therapeutics) Tariff Resilience Score: 5/10 (As of Jul. 05, 2026)


NTLA Intellia Therapeutics Inc NTLA
71 GF Score
Price $17.56
GF Value $20.56
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Intellia Therapeutics Tariff Resilience Score?

Intellia Therapeutics NTLA +1.89% 71 Tariff Resilience Score is 5 as of Jul. 05, 2026. GuruFocus rates NTLA with a GF Score™ of 71/100 and a GF Value™ of $20.56 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,369 Biotechnology companies, Intellia Therapeutics ranks better than 62.38% on this metric.

Intellia Therapeutics has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Intellia Therapeutics has Intellia's reliance on global biotech supply chains exposes it to tariffs on research materials. While its innovative products offer some pricing power, regulatory changes in trade can impact costs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Intellia Therapeutics might have Average Resilient.

Intellia Therapeutics  (NAS:NTLA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Intellia Therapeutics Tariff Resilience Score Related Terms

NTLA vs MLYS, VCEL, NRIX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Intellia Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intellia Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's Tariff Resilience Score falls into.


NTLA
71GF Score
Intellia Therapeutics Inc NTLA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Intellia Therapeutics (NTLA) has a Tariff Resilience Score of 5 as of Jul. 05, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Intellia Therapeutics ranks #515 out of 1369 companies in the Biotechnology industry, placing it in the top 37.6%.
Is Intellia Therapeutics' Tariff Resilience Score too high?
Intellia Therapeutics' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Intellia Therapeutics' value of 5 is 25% above this industry median. Based on the distribution chart, Intellia Therapeutics ranks #515 out of 1369 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Intellia Therapeutics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' Tariff Resilience Score compare to MLYS and VCEL?
According to the Biotechnology industry distribution chart, Intellia Therapeutics ranks #515 out of 1369 companies for Tariff Resilience Score. This puts Intellia Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Intellia Therapeutics' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intellia Therapeutics's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intellia Therapeutics's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.56, compared to a current price of $17.56 — trading 14.6% below its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Intellia Therapeutics' overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current Tariff Resilience Score is 5 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intellia Therapeutics (NTLA) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of $17.56 is trading 14.6% below its estimated GF Value™ of $20.56. GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.

Key valuation signals for NTLA:

  • Tariff Resilience Score: 5
  • GF Value™: $20.56 vs. price of $17.56 (14.6% below fair value)
  • GF Score™: 71/100 with 3 warning signs
  • Industry Position: 25% above the Biotechnology median (#515 of 1369)

No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intellia Therapeutics Business Description

Other Exchanges 0JBU:UK38I:Germany
Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
71GF Score

Get the complete analysis for NTLA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.56
Price
$20.56
GF Value